Key result
Systemic administration of Ant34a completely silenced miR-34a myocardial expression and significantly attenuated doxorubicin-induced cardiac dysfunction, apoptosis, senescence, fibrosis, and inflammation.
Why the study?
Anthracycline cardiotoxicity is a serious clinical issue, and the cardioprotective properties of targeting miR-34a in vivo warranted evaluation.
Does miR-34a silencing with Ant34a prevent doxorubicin-induced cardiac dysfunction in a rat model?
Does miR-34a silencing with Ant34a prevent doxorubicin-induced cardiac dysfunction in a rat model?
Systemic inhibition of miR-34a attenuates doxorubicin-induced cardiotoxicity in rats, suggesting a potential cardioprotective strategy for anthracycline-treated patients.
Answers are grounded in this paper and cite their sources.
MiR-34a silencing may attenuate anthracycline cardiotoxicity in preclinical models; leaves open clinical translation pending human trials.
Cardiotoxicity remains a serious problem in anthracycline-treated oncologic patients. Therapeutic modulation of microRNA expression is emerging as a cardioprotective approach in several cardiovascular pathologies. MiR-34a increased in animals and patients exposed to anthracyclines and is involved in cardiac repair. In our previous study, we demonstrated beneficial effects of miR-34a silencing in rat cardiac cells exposed to doxorubicin (DOXO). The aim of the present work is to evaluate the potential cardioprotective properties of a specific antimiR-34a (Ant34a) in an experimental model of DOXO-induced cardiotoxicity. Results indicate that in our model systemic administration of Ant34a completely silences miR-34a myocardial expression and importantly attenuates DOXO-induced cardiac dysfunction. Ant34a systemic delivery in DOXO-treated rats triggers an upregulation of prosurvival miR-34a targets Bcl-2 and SIRT1 that mediate a reduction of DOXO-induced cardiac damage represented by myocardial apoptosis, senescence, fibrosis and inflammation. These findings suggest that miR-34a therapeutic inhibition may have clinical relevance to attenuate DOXO-induced toxicity in the heart of oncologic patients.
No takes yet. Share an insight, caveat, or question.
Piegari et al. (2020) studied Doxorubicin-induced cardiotoxicity (n=33). Ant34a (miR-34a inhibitor) vs. Scramble control (AntCTL) or saline was evaluated on Cardiac function (diastolic and systolic parameters) and myocardial damage markers (p=<0.05). Systemic administration of Ant34a completely silenced miR-34a myocardial expression and significantly attenuated doxorubicin-induced cardiac dysfunction, apoptosis, senescence, fibrosis, and inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: